Stocks · News reference
Pulse Biosciences announced its financial results for the third quarter ended September 30, 2026, and highlighted the completion of enrollment in its U.S. pivotal IDE study.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules.
Needham & Co. increased its price target for Pulse Biosciences, Inc. from $58 to $64 while maintaining a Buy rating.
Filed: 2026-11-06 AccNo: 0001437749-26-035410 Size: 183 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Pulse Biosciences, Inc. announced its scheduled participation and management presentation at the upcoming Stifel 2026 Healthcare Conference.
Pulse Biosciences has scheduled its third quarter 2026 financial results conference call for November 5, 2026.
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its